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Abstact
Cutaneous regeneration at the wound site involves several intricate and dynamic processes which require a series
of coordinated interactions implicating various cell types, growth factors, extracellular matrix (ECM), nerves, and
blood vessels. Mesenchymal stromal cells (MSCs) take part in all the skin wound healing stages playing active and
beneficial roles in animal models and humans. Exosomes, which are among the key products MSCs release, mimic
the effects of parental MSCs. They can shuttle various effector proteins, messenger RNA (mRNA) and microRNAs
(miRNAs) to modulate the activity of recipient cells, playing important roles in wound healing. Moreover, using
exosomes avoids many risks associated with cell transplantation. Therefore, as a novel type of cell-free therapy,
MSC-exosome -mediated administration may be safer and more efficient than whole cell. In this review, we provide
a comprehensive understanding of the latest studies and observations on the role of MSC-exosome therapy in
wound healing and cutaneous regeneration. In addition, we address the hypothesis of MSCs microenvironment
extracellular vesicles (MSCs-MEVs) or MSCs microenvironment exosomes (MSCs-MExos) that need to take stock of
and solved urgently in the related research about MSC-exosomes therapeutic applications. This review can inspire
investigators to explore new research directions of MSC-exosome therapy in cutaneous repair and regeneration.
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Background
The skin is frequently damaged as a result of acute or
chronic wounds such as extensive burns, trauma or
ulcers of various aetiology. These injuries not only des-
troy the barrier function of the skin but also modify the
sensory perceptions of temperature, pain and touch [1].
Besides, they constitute a painful experience for patients
both physically and mentally, and also cause a huge so-
cioeconomic burden [2]. Therefore, identifying an effect-
ive approach to accelerate cutaneous regeneration and
restore the functions of the injured skin is an urgent
requirment. Besides, this topic has become a significant
challenge in plastic and reconstructive surgery. A novel
therapy for wound healing and regeneration gaining
momentum in the past few years has been the use of
mesenchymal stromal cells (MSCs). MSCs reside in
normal skin and play a critical role in wound healing.
Therefore, the application of exogenous MSCs was pro-
posed to promote regenerative healing of wounded skin
[3]. Although great progress has been made in the appli-
cation of MSCs in wound repair and cutaneous regener-
ation, the limitations inherent to MSCs cell therapy
cannot be ignored. Therefore, the exosomes derived
from MSCs (MSC-exosomes) have gained much atten-
tion as a new potential “cell-free” approach in the field
of wound healing and cutaneous regeneration.
In this review, we discuss the confusing issues related
to MSCs, i.e. the lack of universally accepted criteria for
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defining the MSCs phenotype and/or their functional
properties, and discuss the current clinical trials using
MSCs in wound healing therapy and their current limi-
tations. Then we expound the roles of MSC-exosomes
in cutaneous regeneration and summarize their under-
lying molecular mechanisms. We also clarify the current
scientific problems of MSC-exosomes as the research
trend of “cell-free” therapy. Finally, we bring forward the
key problems which at present need to be solved and ex-
press the hope that more researchers will study this issue
in depth.
Review
The defining and naming of MSCs
Although the biological characteristics and therapeutic
potential of MSCs have been deeply studied, the behav-
ior in vivo and developmental origin of MSCs have not
been clarified yet. With regard to the source of MSCs,
since mesenchymal stem cells exist in almost all tissues
and organs, there is also a popular hypothesis that MSCs
come from perivascular cells [4]. But some researchers
have found that MSCs can also come from tissues with-
out blood vessels and nerves, such as intervertebral disc
[5]. Precisely defining MSCs has been a challenge, as the
field is complicated by inconsistencies related to MSCs
nomenclature and identification criteria. For example,
bone marrow stromal cells, bone marrow stromal stem
cells, MSCs, mesenchymal stem cells, and medical signal
cells, all of which describe the same group of cells, the
widely recognized the acronym, MSC, may be used for
all of them.
Bone marrow stromal cells were first discovered and
reported by Friedenstein AJ in the late 1960s. In 1988,
Owen et al. defined it as bone marrow stromal stem cells
on the basis of previous researchers’ work. In 1991,
Caplan et al. found that there was a group of mesoderm-
derived stem cells with different tissue lines in bone
marrow during embryonic development, and named
these cells as mesenchymal stem cells. The name has
been widely recognized in the world [6]. However, some
scholars believe that there are no sufficient evidences of
self-renewal and multidirectional differentiation poten-
tial ability of mesenchymal stem cells in vivo, and their
biological characteristics do not meet the standards of
stem cells. It is not scientific enough to call stem cells,
which may mislead patients with excessive and unrealis-
tic expectations. Therefore, Horwitz called for the
naming of these cells as “MSCs” at the International
Conference on Cell Therapy [7]. The International Soci-
ety for Cellular Therapy also tried to resolve challenges
in confirming MSC identity by proposing three minimal
criteria for defining human MSCs: (1) the cells must be
plastic-adherent when maintained in standard culture
conditions using tissue culture flasks; (2) ≥95% of the
population must express CD105, CD73, and CD90 and ≤
2% must not express CD45, CD34, CD14, CD11b,
CD79α, or CD19, and HLA class II surface molecules;
and (3) the cells must be able to differentiate into osteo-
blasts, adipocytes, and chondroblasts under standard
in vitro differentiating conditions [8]. Furthermore, the
researchers found that the conditioned medium of MSCs
had biological effects equivalent to MSCs in promoting
wound healing and preventing and treating organ fibro-
sis. It was suggested that the biological effect of MSCs
mainly came from its paracrine mechanism. It was found
that MSCs extracellular vesicles or exocrine bodies also
had almost equivalent biological effects to MSCs. In
2010, Caplan proposed the new name of “medicinal sig-
nal cell, MSC” , because of these cells like “medicine”
homing to the site of injury or disease, secreting bio-
active factors, playing a treatment in situ [9]. In fact, no
matter how precisely MSCs are defined, this does not
affect the applicative prospects of these cells in
treatment.
MSCs in wound healing and cutaneous regeneration
Cutaneous wound healing is a highly organized physio-
logical process that restores the integrity of the skin
following injury. It involves the interplay between vari-
ous populations of cells and is typically categorized into
three reciprocally overlapping phases: inflammation,
proliferation, and maturation [10, 11]. Various MSCs are
also deemed to partake in this process, like the endogen-
ous cutaneous MSCs which include dermal papilla cells
(DPCs) and the dermal sheath cells (DSCs) [12–14].
And the perivascular pericytes and MSCs residing in the
adipose tissue may act as MSCs in vivo [15–17]. How-
ever, in most trauma cases, such as deep burns and
chronic ulcers, there are not enough endogenous cuta-
neous MSCs to partake in wound self-repair because of
the missing dermal tissue. Therefore, exogenous MSCs
have been applied to wounds to exploit their physio-
logical therapeutic actions in wound healing. Regardless
of the caveats in their identity or source, MSCs were re-
ported to exert beneficial effects on both wound healing
and scarring. Since MSCs are endowed with a wide differ-
entiation potential, they are attractive treatment options
in regenerative medicine and, over the past decade, have
rapidly emerged as a cell therapeutic tool for advancing
wound healing.
Most of the evidence related to MSCs activity in
wound healing comes from bone marrow-derived MSCs
(BMSCs) and other tissue of origin MSCs used in animal
models, with only a small number of published clinical
studies. In addition, these clinical studies are based on
the transplantation of autologous BMSCs [18–21].
BMSCs are collected via bone marrow aspiration, which
is a safe but painful and invasive procedure, sometimes
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associated with complications such as infection and
hemorrhage [22]. Additionally, bone marrow is a limited
resource; there occurs an age-dependent reduction in
bone marrow cells numbers [23]. Therefore, MSCs of
several different sources have been used as alternative
choices, including adipose-derived stromal cells (ADSCs),
dermal MSCs, and MSCs from amniotic fluid and umbil-
ical cord. ADSCs and dermal MSCs are abundantly
available in fat and skin tissues, can be harvested with
minimally invasive procedures, and their use is devoid of
ethical controversies making them good alternatives to
BMSCs. ADSCs and dermal MSCs have similar biological
characteristics, immunogenicity, and potential to differen-
tiate to BMSCs [24–29] . In clinical trials currently under
evaluation [30], ADSCs have demonstrated a therapeutic
potential in burn wounds and ulcers. Likewise, dermal
MSCs have shown beneficial effects on wound healing in
clinical trials [31, 32]. Although, there are no clinical trials
related to human amniotic membrane-derived MSCs
(hAM-dMSCs) and human umbilical cord-derived MSCs
(hUC-dMSCs) in wound healing have appeared currently.
These promising clinical studies indicate that MSC-based
therapies are safe and potentially efficacious, with no indi-
cation that any particular MSC tissue origin has an advan-
tage for wound healing over the others [12].
Current limitations of MSCs application in wound healing
Despite progression in MSC-based therapies, many chal-
lenges to overcome before MSCs can be used for effect-
ively for wound healing treatment. The drawbacks in the
clinical application of MSCs have emerged gradually:
Firstly, there is considerable heterogeneity in the delivery
protocols, wound models, and MSCs populations among
published studies which makes it hard to determine the
impact of timing of delivery, number of cells delivered,
and site of delivery on MSCs engraftment upshots [33].
Secondly, there is no evidence that MSCs differentiate
into phenotypes typical of resident cutaneous cells during
skin wound healing [34]. Increasing evidences suggest that
MSCs secrete bioactive factors through endocrine and
paracrine pathways to target tissues and cells, thereby re-
ducing wound inflammation and promoting tissue repair
[33]. So the criteria to assess the need for direct MSCs
transplantation onto wounds are to be determined. Finally
and importantly, current challenges with the use of MSCs
concern the lack of universally accepted criteria for defin-
ing the MSCs phenotype or their functional properties,
and further clinical trials are needed to demonstrate the
potential therapeutic benefits of MSCs in vast cohorts of
patients [33].
Exosomes derived from MSCs (MSC-exosomes)
Exosomes are cell-derived vesicles that are present in
many and perhaps all eukaryotic fluids, including blood,
urine, and growth media of cell cultures [35]. The reported
diameter of exosomes is between 30nm and 100 nm, which
is larger than low-density lipoproteins (LDL) but much
smaller than, for example, other vesicles or red blood cells.
Exosomes are either released from the cell when multivesi-
cular bodies fuse with the plasma membrane or released dir-
ectly from the plasma membrane [36]. Reportedly, the
contents within exosomes are manifold including cytokines,
proteins, lipids, mRNAs, miRNAs, noncoding RNAs
(ncRNAs), ribosomal RNAs (rRNAs), cytokines and chemo-
kines [37]. Accumulating lines of evidence shown that exo-
somes have specialized functions and play keys role in
processes such as coagulation, intercellular signaling, and
waste products management [38]. Consequently, the interest
in the clinical applications of exosomes is growing. Their
functions include immune regulation, vascular regeneration
promoting, mediation of cell proliferation, differentiation,
migration and apoptosis, preserving the body physiological
condition, and partaking in disease processes [39].
MSC-derived exosomes (MSC-exosomes) exhibit the
characteristics of resource cells, which can promote cell
self-repair and tissue regeneration, restore tissue homeo-
stasis and accelerate wound repair in injury areas [40].
In recent years, some studies have suggested that MSCs
have a strong ability to produce exosomes [41]. Most re-
searchers believe that MSC-exosomes are the main ef-
fective paracrine component of MSCs and play
biological effect almost equivalent to those of whole
MSCs. In comparison with MSCs, MSC-exosomes have
the following advantages: First, MSC-exosomes exert in-
tense biological effects because they directly fuse with
target cells. Second, MSC-exosomes can be stored and
transported at − 70 °C for a long time since their effect-
ive components are protected by the exosome’s plasma
membrane, which is not easy to be destroyed. Third, the
concentration, dose, route and time of use are easy to
control. Last but not least, there is no risk of immune
rejection and tumorigenesis caused by cell transplant-
ation therapy [42].
MSC-exosomes in wound healing and cutaneous
regeneration
The typical skin regeneration process can be summarized
as three overlapping stages: inflammation phase, prolifera-
tion phase (cell proliferation and reepithelization) and
remodeling phase [10–12]. Currently, all the researches on
MSC-exosomes in wound healing and cutaneous regener-
ation are also focussed on the role of MSC-exosomes in the
above three stages.
Mechanism of MSC-exosomes behavior on inflammation
phase
Inflammation is a body self-defense mechanism in
response to harmful stimuli, and an acute and well-
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regulated inflammatory response is beneficial for normal
wound healing [43]. By contrast, a chronic and dysregulated
inflammatory response may delay wound healing and
promote fibrosis, excessive scar formation or inhibition of
re-epithelialization [44]. Macrophages are prominent in-
flammatory cells which play an important role in the
cutaneous regeneration process. Recent evidence has sug-
gested that macrophages influence each stage of cutaneous
regeneration and present a proinflammatory M1 phenotype
and an anti-inflammatory M2 phenotype. Macrophage dys-
function may promote excessive inflammation or fibrosis
[45]. MSC-derived extracellular vesicles, including MSC-
exosomes, promote the significant switching of recipient’s
macrophages toward the anti-inflammatory M2 phenotype
[46]. In addition, MSC-exosomes can regulate the activa-
tion, differentiation, and proliferation of B lymphocytes
and can also suppress T-lymphocyte proliferation. MSC-
exosomes can convert activated T lymphocytes into the
T-regulatory phenotype, thereby exerting immunosup-
pressive effects [47, 48]. Furthermore, the regulation of in-
flammatory factors plays an important role in skin tissue
regeneration, and excessive production of cytokines may
lead to tissue injury [49]. Exosomes derived from different
kinds of MSCs can mitigate the inflammatory response
caused by multiple stimuli through the down-regulation
of proinflammatory enzymes, like inducible nitric oxide
synthase (iNOS) and cyclooxygenase (COX)-2, and of
cytokines and chemokines, like tumor necrosis factor
(TNF)-α, interleukin (IL)-1β and monocyte chemoattract-
ant protein (MCP)-1. Moreover, in many disease models,
MSCs-exosomes can drive the up-regulation of an anti-
inflammatory cytokine, i.e. IL-10, which reportedly plays a
critical role in the control of cutaneous wound inflamma-
tion and scar formation [50–52]. Various studies have
revealed that MSC-exosomes exert immunomodulatory
effects through specific miRNAs. By analyzing miRNA ex-
pression profiles, they showed that hUC-dMSCs exhibit
the highest content of three miRNAs (miRNA- 21,
miRNA-146a and miRNA-181c) specifically related to the
regulation of immune response and inflammation [53, 54].
Furthermore, other studies showed that hUC-dMSCs-
exosomes carrying miRNA-181c attenuated the burn-
induced very intense inflammation by down-regulating
the Toll-like receptor 4 (TLR4) signaling pathway [51].
Anti-inflammatory miRNAs (miRNA-124a, miRNA-
125b) detected within exosomes have been implicated
in the post-transcriptional silencing of chemokines and
cytokines (e.g., TNF-α and MCP-1) which instead con-
tribute to the persistence of inflammatory cellular infil-
trations in wound healing [55, 56]. Overall, the specific
molecular mechanisms through which MSC-exosomes
inhibit inflammation in the setting of wound healing
and cutaneous regeneration also need to be clarified by
further studies.
Mechanism of MSC-exosomes behavior on proliferation phase
In the proliferation phase, neoangiogenesis, collagen depos-
ition, granulation tissue formation, re-epithelialization, and
wound contraction concur [57]. The formation of neoan-
giogenesis is a crucial step in various physiological and
pathological processes, including wound healing and tissue
repair [10, 58, 59]. MSC-exosomes are enriched in various
angiogenesis-related proteins and RNAs, including miRNAs
that could activate multiple signaling pathways in endothe-
lial cells. The same exosomes can induce the expression of
numerous trophic factors [60]. In addition, Li et al.revealed
that transplanted human umbilical cord blood endothelial
progenitor cells-derived exosomes (EPC-exosomes) could
upregulate the expression of angiogenesis-related mole-
cules, including vascular endothelial growth factor (VEGF)
- A, vascular endothelial growth factor receptor (VEGFR)-2,
fibroblast growth factor (FGF)- 1, E-selectin, angiopoietin-
1, Chemokine (C-X-C motif) ligand 16, IL- 8, and endothe-
lial nitric oxide synthase (eNOS), in vascular endothelial
cells [61]. Furthermore, the mRNA levels of matrix metallo-
proteinase (MMP)-9 were remarkably decreased in endo-
thelial cells stimulated with EPC-exosomes [61]. The study
has found that significantly higher expression of MMP-9
was associated with poor wound healing [62]. Thus, the
proangiogenesis effects of EPC-exosomes may be partially
attributed to their inhibition of MMP-9. However, it is still
necessary to reveal their further mechanisms about angio-
genesis in wound repair.
Cell proliferation and skin re-epithelization are crucial
for cutaneous regeneration. Skin fibroblasts play a relevant
role in skin tissue repair and regeneration: they participate
in wound contraction, extracellular matrix deposition,
tissue remodeling, and so on [63]. MSC-exosomes can be
internalized and hence transport their contents, such as
proteins and RNAs, into the receiving cells to regulate their
proliferation and migration. It has been proven that MSC-
exosomes regulate the proliferation and migration of fibro-
blasts by modulating the expression of growth factors and
their related genes [64–66] thus taking part to the forma-
tion of granulation tissue and to the synthesis of colla-
gen which provides structural support for wound repair
[67, 68]. Some scholars treated fibroblasts extracted
from chronic diabetic ulcer wounds with exosomes de-
rived from BMSCs. The results showed that exosomes
could promote the proliferation and migration of fibroblasts
in a dose-dependent manner. Human fibrocyte-derived
exosomes contain proteins and miRNAs with diverse bio-
logical activities, and these exosomes accelerated wound
healing by inducing the migration and proliferation of skin
cells in the diabetic rat model [55].
In addition, the study found that exosomes derived from
hUC-dMSCs promoted the proliferation of skin cells (dermal
fibroblasts, epidermal keratinocytes) in a dose-dependent
manner. In in vivo experiments, the researchers used local
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multi-point injection to evaluate the effect of exosomes by
injecting exosomes around deep II degree burn wounds
models. The results showed that exosomes derived from
hUC-dMSCs accelerated wound healing, promoted re-
epithelialization, and increased the expression of cytokeratin-
19 (CK19), proliferating cell nuclear antigen (PCNA) and
collagen I [69, 70]. Moreover, transplanting human amniotic
epithelial cell-derived exosomes (hAEC-exosomes) to wound
sites accelerated wound closure and re-epithelization [71].
Mechanism of MSC-exosomes behavior on remodeling phase
Extracellular matrix (ECM) mainly constituents of four
kinds of substances, namely collagen, non-collagen (fi-
bronectin, laminin), elastin, proteoglycans, and amino-
glycans. The key to ECM reconstruction is the synthesis
and degradation of collagen. Insufficient or excessive
ECM formation can cause the wound surface not to heal
or scar formation. MSC-exosomes have been shown to
regulate ECM re-synthesis in addition to participating in
the above cellular effects. Reportedly, exosomes derived
from hUC-dMSCs can promote the de novo synthesis of
type I collagen and elastin [65], and exosomes from the
inducing process which human induced pluripotent
stem cells (hiPSCs) had differentiated to dermal MSCs
(dMSCs) can promote the synthesis of type I collagen,
type III collagen, and elastin proteins, and enhance the
expression levels of type I collagen, type III collagen, and
elastin mRNAs [72]. These findings prove that MSC-
exosomes can promote the regeneration of ECM and thus
advance wound healing. The exosomes derived from
ADSCs (ADSCs-exosomes) can also regulate collagen syn-
thesis at different stages of wound healing, accelerate
wound healing through an early stage increase in the pro-
duction of type I and type III collagen, and inhibit collagen
synthesis in a late stage, thereby reducing scar formation
[73]. In a skin-defect mouse model, exosomes derived from
hUC-dMSCs did prevent scar formation by inhibiting the
differentiation of fibroblasts into myofibroblasts [74]. More-
over, the research reported that hAEC-exosomes exerted
beneficial effects in a rat model of scarless wound healing.
High concentration of hAEC-exosomes partly reduced
ECM deposition by stimulating the expression of MMP-1
[71]. In addition, Wang et al. posited that ADSCs-exosomes
can inhibit the formation of type III/type I collagen by dir-
ectly acting on fibroblasts [75]. In a study applying traceable
ADSCs-exosomes to repair skin defects in mice, the exo-
somes were recruited around the skin wounds to perform
their functions and to increase the rate of wound healing.
Histological analysis showed that exosomes could promote
collagen synthesis in the early stage of wound healing, and
inhibit collagen synthesis in the late stage to inhibit scar tis-
sue formation [64] .All these studies indicate that MSC-
exosomes play a key role in ECM remodeling, which is also
the possible mechanism of reducing scar formation.
Hypothesis of MSCs-MEV or MSCs-MExos and future
perspectives
Over the past decades, a deep-going research has taken
place concerning MSCs and MSC-exosomes roles in the
field of wound repair and cutaneous regeneration. MSC-
exosomes based therapy is emerging as a promising
technique able to promote wound healing and minimize
scarring. Accordingly, being a cell-free alternative ther-
apy, MSC-exosomes enjoy many advantages, being easy
to be prepared, stored and transported, easy to be dosed,
and easy to be administered at the time of choice. They
also appear to have a high therapeutic efficiency, and to
carry no risk of immune rejection and tumorigenesis.
Thus, MSC-exosomes are endowed with a remarkable
potential for cutaneous regeneration and could effect-
ively replace whole MSCs-based therapy. The molecular
mechanisms through which the MSC-exosomes bring
into effect cutaneous regeneration will be fully brought
to light by further studies looking into their specific con-
tents and functions. At present, most of the mechanisms
discussed were studied in rodents, but animal physiology
cannot always be extrapolated to humans. So further
clinical trials using exosomes of human origin are
needed to definitively demonstrate the skin regenerative
therapeutic potential of MSCs in a large number of pa-
tients. However, there are still key scientific issues that
need to be resolved before.
Although MSCs derived from different tissues do not have
the same differentiation potency, their physical and bio-
logical functions show a high level of consistency [76, 77].
So it might not be considered as an obstacle that which
MSCs should be chosen to produce exosomes. However,
MSCs transplantation has different biological effects in
different stages of wound healing or in different diseases. In
fact, the fate and paracrine effects of MSCs are closely re-
lated to the microenvironment of their transplantation site
[78, 79]. For instance, studies have shown that transplant-
ation of MSCs into organs and tissues can up-regulate the
expression of VEGF and accelerate the regeneration and
healing of injured tissues [80]; But in some studies concern-
ing tumors, researchers have found that MSCs can down-
regulate the expression of VEGF and inhibit the angiogen-
esis supporting the growth of tumors [81, 82]. Our studies
also corroborate that MSCs derived from different sources
can promote fibroblast proliferation and migration through
the paracrine effect, and up-regulate the expression of trans-
forming growth factor (TGF) -β1, collagen I and angiogen-
esis factors in fibroblasts and wound tissues to advance the
formation of granulation tissue and accelerate wound re-
epithelialization. But when MSCs were transplanted after
wound re-epithelialization, the biological effects were chan-
ged by the paracrine effect in in vivo and in vitro studies
(e.g., the expression of fibrosis-related factors such as TGF-
β1, α-smooth muscle actin (α-SMA) and collagen I was
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down-regulated, and the expression of anti-fibrosis factors
such as TGF-β3 and Decorin was up-regulated to hinder
the formation of the scar.
Recent research also has shown that stimulating hUC-
dMSCs with interferon (IFN) -γ if there were in a simu-
lated inflammatory microenvironment can significantly
increase the release of MSCs-exosomes. IFN-γ can en-
hance the immune regulatory activity of hUC-dMSCs
acting like a “license” factor and increase the proportion
of CD4+, CD25+ and Foxp3+ T cells among the whole
Regulatory T cells (Tregs) [83]. Lipopolysaccharide
(LPS) pretreated hUC-dMSCs secrete more proteins
than untreated ones, and the exosome derived from
LPS-pretreated hUC-dMSCs are rich in miRNA let-7b,
which can induce macrophages to take on the anti-
inflammatory M2 phenotype [53]. (Fig. 1). In addition,
the research showed that 1–2% hypoxia environment,
media with TNF-α, and three-dimensional culture sys-
tem all had been found significantly change the compo-
nents of MSCs paracrine factors in vitro culture [84].
(Fig. 2) The release and components of MSC-exosomes
can be modulated by changing the cell culture condi-
tions, that is the microenvironment in which the cells
live.
However, all the current studies on the mechanisms of
MSC-exosomes activities are based on the MSC-exosomes
isolated from the standard culture medium in vitro. This
obviously contradicts the important scientific argument
that the paracrine effect of MSCs is closely related to their
microenvironment. In other words, MSC-exosomes se-
creted in different microenvironments have different
components which exert dissimilar biological effects. This
important scientific issue has been ignored by almost all
researchers of studying MSCs-EVs or MSC-exosomes.
Conclusions
Wound healing and cutaneous regeneration is a compli-
cated and dynamic process, and the same is true of other
diseases. If we only isolate MSC-exosomes from condi-
tioned medium supernatants under standard laboratory
culture conditions, then use them as a cell-free therapy
for different diseases or different pathological stages of
Fig. 1 Under the stimulating human umbilical cord-derived mesenchymal stromal cells (hUC-dMSCs) with different factors, the quantities and
components of exosomes had changed. Then, the biological characteristics of target cells also have changed after received the exosomes. (a) In a
normal situation, target cells receive microvesicles and exosomes released from MSCs. (b) Stimulating hUC-dMSCs with interferon (IFN)- g, there
were in a simulated inflammatory microenvironment that can significantly increase the release of MSCs-exosomes. Then, it can enhance the
immunomodulatory activity of hUC-discs and increase the proportion of CD4+, CD25+ and Foxp3+T cells in the entire regulatory T cells. (c)
Stimulating hUC-dMSCs with lipopolysaccharide (LPS) can secrete more exosomes than untreated ones, and the exosome derived from them are
rich in miRNA let-7b, which can induce macrophages to exhibit the anti-inflammatory M2 phenotype by the specific signal pathway
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the same disease, it will be obviously difficult to “accur-
ately” achieve an effective cell therapy based on MSCs.
Even if, we can not fully elucidate its essence and
mechanism of inducing MSCs paracrine effect, and it
is difficult or even impossible to simulate the micro-
environment completely at present. However, we can
imitate it in the vitro culture systems which are
based on the known environmental factors, such as
inflammatory factors in wound inflammation stage,
and hypoxia factors in ischemic anoxic wounds.
There is no doubt, the complexity of wound micro-
environment should not be the excuse of ignoring
the microenvironmental factors in studying MSCs-
EVs or MSCs-Exos.
Therefore, we propose the hypothesis of MSCs-MEV or
MSCs-MExos which takes stock of the conditions in
which the exosomes were produced as related to their
therapeutic applications. We also hope that more scholars
will pay a greater attention to this scientific problem,
which is to find more and more suitable methods simulat-
ing the damaged site microenvironment of diverse dis-
eases or of different pathological stages of the same illness.
If these key problems can be solved, MSCs will have a
significant impact on wound healing and cutaneous regen-
eration, besides other diseases, as a cell-free therapy.
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